KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EBITDA (2016 - 2025)

Historic EBITDA for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$31.7 million.

  • Nektar Therapeutics' EBITDA rose 778.28% to -$31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.1 million, marking a year-over-year increase of 3591.34%. This contributed to the annual value of -$105.2 million for FY2024, which is 6010.45% up from last year.
  • Latest data reveals that Nektar Therapeutics reported EBITDA of -$31.7 million as of Q3 2025, which was up 778.28% from -$36.2 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year EBITDA high stood at $14.3 million for Q4 2024, and its period low was -$152.8 million during Q2 2022.
  • Moreover, its 5-year median value for EBITDA was -$50.6 million (2023), whereas its average is -$68.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 4181.76% in 2021, then soared by 14281.58% in 2024.
  • Quarter analysis of 5 years shows Nektar Therapeutics' EBITDA stood at -$112.9 million in 2021, then soared by 53.53% to -$52.5 million in 2022, then soared by 36.13% to -$33.5 million in 2023, then skyrocketed by 142.82% to $14.3 million in 2024, then crashed by 320.74% to -$31.7 million in 2025.
  • Its EBITDA was -$31.7 million in Q3 2025, compared to -$36.2 million in Q2 2025 and -$44.5 million in Q1 2025.